Clinigen Group PLC (LON:CLIN) insider Shaun Edward Chilton bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were purchased at an average cost of GBX 416 ($5.47) per share, for a total transaction of £41,600 ($54,722.44).
Shares of Clinigen Group stock opened at GBX 478.40 ($6.29) on Friday. The business has a 50-day moving average of GBX 724.83 and a 200 day moving average of GBX 847.21. Clinigen Group PLC has a 12 month low of GBX 600.50 ($7.90) and a 12 month high of GBX 1,069 ($14.06). The stock has a market capitalization of $635.55 million and a price-to-earnings ratio of 46.00. The company has a debt-to-equity ratio of 82.15, a current ratio of 1.12 and a quick ratio of 0.86.
Clinigen Group (LON:CLIN) last announced its earnings results on Tuesday, February 25th. The company reported GBX 30.80 ($0.41) EPS for the quarter, missing analysts’ consensus estimates of GBX 31 ($0.41) by GBX (0.20) ($0.00). Equities research analysts anticipate that Clinigen Group PLC will post 2573.0001139 earnings per share for the current year.
The company also recently announced a dividend, which will be paid on Friday, April 17th. Investors of record on Thursday, March 19th will be issued a dividend of GBX 2.15 ($0.03) per share. This represents a yield of 0.29%. The ex-dividend date of this dividend is Thursday, March 19th. Clinigen Group’s dividend payout ratio (DPR) is 0.67%.
A number of equities analysts recently commented on the company. Peel Hunt restated a “buy” rating on shares of Clinigen Group in a report on Thursday, March 5th. Royal Bank of Canada restated a “top pick” rating and set a GBX 1,500 ($19.73) target price (down from GBX 1,600 ($21.05)) on shares of Clinigen Group in a report on Friday, March 20th. Finally, Liberum Capital restated a “buy” rating on shares of Clinigen Group in a report on Tuesday.
Clinigen Group Company Profile
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.